Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
189
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Ruxolitinib Treatment During Myelofibrosis Leads to Cutaneous Mycobacterium marinum Infection: A Case Report

Xiaonan Chen1 Department of Hematology, Affiliated Hospital of Weifang Medical University, Weifang, People’s Republic of ChinaView further author information
,
Dong Zhang2 Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-0621-0645View further author information
ORCID Icon,
Teng Wang3 Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3203-928XView further author information
ORCID Icon &
Weiyuan Ma2 Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4549-3166View further author information
ORCID Icon
Pages 1499-1503 | Received 22 Mar 2023, Accepted 27 May 2023, Published online: 13 Jun 2023

References

  • Kotyla PJ, Engelmann M, Giemza-Stoklosa J, et al. Thromboembolic adverse drug reactions in janus kinase (jak) inhibitors: does the inhibitor specificity play a role? Int J Mol Sci. 2021;22(5):2449. doi:10.3390/ijms22052449
  • Clarke B, Yates M, Adas M, et al. The safety of jak-1 inhibitors. Rheumatology. 2021;60(Suppl 2):ii24–ii30. doi:10.1093/rheumatology/keaa895
  • Winthrop KL. The emerging safety profile of jak inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243. doi:10.1038/nrrheum.2017.23
  • Kompa KG, Trottier CA, Hyman CL, Kohli R. Disseminated Mycobacterium avium complex myositis in a patient with graft-versus-host disease. Open Forum Infect Dis. 2022;9(8):ofac385. doi:10.1093/ofid/ofac385
  • Sayabovorn N, Chongtrakool P, Chayakulkeeree M. Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review. BMC Infect Dis. 2021;21(1):27. doi:10.1186/s12879-020-05703-2
  • Anand K, Burns EA, Ensor J, Rice L, Pingali SR. Mycobacterial infections with ruxolitinib: a retrospective pharmacovigilance review. Clin Lymphoma Myeloma Leuk. 2020;20(1):18–23. doi:10.1016/j.clml.2019.08.008
  • Johnson MG, Stout JE. Twenty-eight cases of mycobacterium marinum infection: retrospective case series and literature review. Infection. 2015;43(6):655–662. doi:10.1007/s15010-015-0776-8
  • Agashe RP, Lippman SM, Kurzrock R. Jak: not just another kinase. Mol Cancer Ther. 2022;21(12):1757–1764. doi:10.1158/1535-7163.MCT-22-0323
  • Roskoski R. Janus kinase (jak) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacol Res. 2022;183:106362. doi:10.1016/j.phrs.2022.106362
  • Clark JD, Flanagan ME, Telliez JB. Discovery and development of janus kinase (jak) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038. doi:10.1021/jm401490p
  • Harrison C, Kiladjian JJ, Al-Ali HK, et al. Jak inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798. doi:10.1056/NEJMoa1110556
  • Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435. doi:10.1056/NEJMoa1409002
  • Sailliet N, Brosseau C, Robert JM, et al. Role of jak inhibitors and immune cells in transplantation. Cytokine Growth Factor Rev. 2019;47:62–73. doi:10.1016/j.cytogfr.2019.05.002
  • Wang FY, Wang XM, Wang C, et al. Suppression of Mcl-1 induces apoptosis in mouse peritoneal macrophages infected with Mycobacterium tuberculosis. Microbiol Immunol. 2016;60(4):215–227. doi:10.1111/1348-0421.12368
  • Daza-Cajigal V, Albuquerque AS, Young DF, et al. Partial human Janus kinase 1 deficiency predominantly impairs responses to interferon gamma and intracellular control of mycobacteria. Front Immunol. 2022;13:888427. doi:10.3389/fimmu.2022.888427
  • Barraco F, Greil R, Herbrecht R, et al. Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis. Br J Haematol. 2020;191(5):764–774. doi:10.1111/bjh.16729
  • Lussana F, Cattaneo M, Rambaldi A, et al. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339–347. doi:10.1002/ajh.24976
  • Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis. 2006;25(10):609–613. doi:10.1007/s10096-006-0201-4
  • Hashish E, Merwad A, Elgaml S, et al. Mycobacterium marinum infection in fish and man: epidemiology, pathophysiology and management; a review. Vet Q. 2018;38(1):35–46. doi:10.1080/01652176.2018.1447171

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.